

If you're Cloning PCR products... Think Fast Cloning PCR products...

European Headquarters: Invitrogen BV P.O. Box 2312 9704 CH Groningen The Netherlands Tel: +31 (0) 50 5299 299 Fax: +31 (0) 50 5299 281 Email: tech_service@invitrogen.nl www.invitrogen.com International Toll Free Numbers: Tel: 00800 5345 5345* Fax: 00800 7890 7890* This number operates in all European countries excluding Finland and Sweden Finland: Tel: 900800 5345 5345 Fax: 909800 7890 7890 Sweden: Tel: 009800 5345 5345 Fax: 009800 7890 7890

Distributors:

Austria 0222 889 18 19 Australia 1 800 882 555 China 010 6255 3477 Hungary 01 280 3728 India 91 80 8391453 Israel 02 584 1111 Italy 02 38 19 51 Japan 03 5684 1622 ots of things are fast. Jet planes. Bullet trains. Sports cars. With TOPO[™] TA Cloning[®] you can add cloning PCR products to the list. *Superfast* Cloning. In just 5 minutes, TOPO[™] TA Cloning[®] lets you ligate *Taq*amplified PCR products right on your bench top. Simply add 1 µl of your PCR (no clean-up needed!) to the topoisomerase I-activated vector, and 5 minutes later you're ready to transform. **No Extra Steps.** TOPO[™] TA Cloning[®] eliminates the need for special primers and vector preparation. There's also no post-PCR modifications. And best of all, there's no waiting. With TOPO[™] TA Cloning[®],



More Recombinants. TOPO" TA Cloning* is not just fast-it's efficient. It yields up to 95% recombinants so you'll easily find a positive clone.

Think Fast. If you want to clone your PCR products fast, just call Invitrogen and order a TOPO[™] TA Cloning[®] Kit. It comes with your choice of cloning-ready vector (pCR[®]2.1-TOPO or pCR[®]II-TOPO), competent cells, and other reagents to optimize your results. So think fast. Order the TOPO[™] TA Cloning[®] Kit today.

Circle No. 23 on Readers' Service Card

Malaysia 03 432 1357 Poland 058 341 47 26 Portugal 01 453 7085 Singapore 65 2922130 South Korea 02 569 6902 Spain 03 450 2601 Taiwan 886 2 238 10844 Thailand 246 7243

From all other countries, call our European headquarters at +31 (0) 50 5299 299.



1600 Faraday Avenue Carlsbad, California 92008 Tel: 1-800-955-6288 Fax: 760-603-7201 Email: tech_service@invitrogen.com http://www.invitrogen.com



GeneAmp® PCR System 9700

ROBOCYCLER

Our competitors are turning into pretty good salesmen... for Stratagene!

Compare published temperature uniformity specs:

MJ Research says: "±0.4°C within 30 sec. of arrival @ 90"."

Perkin Elmer says: "±0.5°C, 30 seconds after clock start...

The Stratagene RoboCycler® gives you ±0.1°C at clock start!

No equilibration time.

Reliable, predictable, reproducable well-to-well temperature uniformity start-to-finish every time.

Robo Cycler*

Uniformity.

PE Applied Biosystems

MD Research says They have temperature uniformity +0.4°C within 30 sec of arrival at temperature.

aphica ent; ng, bir suse suft

Take the mystery out of your PCR by putting Uniformity in!

It's not just the enzyme. The quality of your PCR, realls can be affected by the primer-template annealing opecificity, the buffers used and the ratio of meaction components. Heating and cooling design, well-to-well uniformity and ramping control ean also have dramatic affects on PCR, results, but are often overhooked when choosing a temperature cycler. These Characteristics will determine PCR product quality, reaction, reproducibility, cycling speed and fluid temperature variability within and between neaction wells during each cycle. It's not just the enzyme.

PEITTER THERMAL CYC

The PTC 200 DNA E

It's the instrument.

The RoboCycler® temperature cycler's robotic arm moves samples from one pre-equilibrated block to another, eliminating the need for temperature ramping. The RoboCycler system for temperature ramping. The Roose-Jean-blocks have sufficient mass to be isothermal upon-reaching a set temperature, so each block eshibits an unparalleled well-to-well uniformity of ±0.1°C. Other popular temperature cycler designs use Peluer electronics to heat and cool a single block.

The Peltier electronic heater plate is attached to the underside of the block. The block ramps to the first

temperature for a set dwell time, then ramps to the temperature for a set dwell time, then ramps to me next programmed temperature. During temperature ramping, the Peltier block acts as a heat pump to pump heat to or pull heat away from the sample. In order to change temperature quickly.

a Peltier cycler block must have minimal thermal mass, but this design does not hold even steady state temperatures well, resulting in greater well-to-well

RoboCycler' temperature cyclers set the industry standard for the best well-to-well temperature uniformity and temperature control. Action Eliner Says Entratacene's Robol yder's ±0.5°C 30 sec Action dat start. Entratacene's Robol yder's ±0.1°C AT Clark Start This Equilibration Time Uniformity & Predictibility from start=to-Endor Uniformity & Predictibility from start=to-Endor Eddol yder's The ONES

· Better temperature control means

superior temperature uniformity.

Better temperature uniformity means consistent, reliable and reproducible well-to-well PCR results.



UNITED STATES AND CANADA INTERNET

ratagene.com STRATAGENE EUROPE:

Austria: 017 956 7036 Belgium: 027 13 12 11 Germany: 0699 509 6197 Netherlands: 0800 023 0448 Switzerland: 01 800 9045 United Kingdom: 0171 365 1056

DISTRIBUTORS For a list of worldwide distributors, please visit the Stratag

Circle No. 37 on Readers' Service Card

www.stratagene.com



RoboCycler^{*} 40 or 96 Temperature Cycler BoboCycler^{*} Gradient 40 or 96 Temperature Cycler RoboCycler^{*} Infinity Temperature Cycler with interchangable 40-,96- and 384-well blocks STRATAGENE

VOLUME 283



15 JANUARY 1999

Cover The cover photograph illustrates a range of rice varieties. Such diversity provided the grist for plant breeders who developed today's high-yielding strains. Now the world needs another boost in grain harvests, and agricultural researchers are pinning their hopes on biotechnology. See the News stories beginning on page 310. [Photo: International Rice Research Institute and Consultative Group on International Agricultural Research]



303 What our early ancestors ate

	302	U.S. R&D SPENDI Get Top Billing in
6	▼ 303 335 368	PALEOANTHROPOL Hominids Eat Me
	305	AIDS: T Cell Proc Exhausted?
Real Provide P	▼ 306 397	NEUROBIOLOGY: H May Calm Hyper
and the second s	307	SCIENTIEIC EYCHA

EWS

U.S. R&D SPENDING: Computing, NSF to
Get Top Billing in 2000 Budget
BALFOANTUPOPOLOCY Did Early African

I Early African eat?

NEWS OF THE WEEK

- uction Slowed, Not
- **How Stimulant Drugs** ractivity
- ANGES: DOE Blocks **Physicists From Indian Meeting**
- 307 **FREEDOM OF INFORMATION: Scientific** Leaders Balk at Broad Data Release
- 309 **Policy Initiatives**

NEWS FOCUS

NUMBER 5400

310 FUTURE FOOD: Crop Scientists Seek a **New Revolution**

> Crossing Rice Strains to Keep Asia's Rice **Bowls Brimming**

BIOENGINEERING: Genetic Engineers Aim to Soup Up Crop Photosynthesis

- 317 **CLIMATE CHANGE: Landscape Changes** Make Regional Climate Run Hot and Cold
- **AMERICAN ASTRONOMICAL SOCIETY:** 319 Seeking Lasting Truths Among the Stars
- 320 **AMERICAN GEOPHYSICAL UNION: New Data** Hint at Why Earth Hums and Mountains Rise

DEPARTMENTS	R
NETWATCH 295	
THIS WEEK IN SCIENCE 297	353
SCIENCESCOPE 305	₹357
RANDOM SAMPLES 323	550
CONTACT SCIENCE 325	362
New Products 409	
	365
	SCIENCE (IS
MERICAN	Science, 120

SCIENCE (ISSN 0036-8075) is published weekly on Friday, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005. Periodicals Mail postage (publication No. 484460) paid at Washington, DC, and additional mailing offices. Copyright © 1999 by the American Association for the Advancement of Science. The title SCIENCE is a registered trademark of the AAAS. Domestic individual membership and subscription (51 issues): \$110 (\$62 allocated to subscription). Domestic institutional subscription (51 issues): \$325; Foreign postage extra: Mexico, Caribbean (surface mail) \$55; other countries (air assist delivery) \$90. First class, airmail, student, and emeritus rates on request. Canadian rates with GST available upon request, GST #1254 88122. Publications Mail Agreement Number 1069624. Printed in the U.S.A.

▼ 368 303

335

292

SCIENCE

ADVANCEMENT OF

15 JANUARY 1999 VOL 283 SCIENCE www.sciencemag.org

SEARCH

GENOMICS: India Prepares Research,

RESEARCH ARTICLES Far-Ultraviolet Imaging Spectroscopy of Io's Atmosphere with HST/STIS F. L. Roesler, H.W. Moos, R. J. Oliversen, R. C. Woodward Jr., K. D. Retherford, F. Scherb, M. A. McGrath, W. H. Smyth, P. D. Feldman, D. F. Strobel

Fusion-Competent Vaccines: Broad

REPORTS

in Earth's Mantle S. Chakraborty, R.

N. L. Ross, R. J. Angel

Enhancement of Cation Diffusion Rates

Across the 410-Kilometer Discontinuity

Knoche, H. Schulze, D. C. Rubie, D. Dobson,

Phytoplankton Community Structure

and the Drawdown of Nutrients and CO2

in the Southern Ocean K. R. Arrigo, D. H.

Robinson, D. L. Worthen, R. B. Dunbar, G. R.

DiTullio, M. VanWoert, M. P. Lizotte

Neutralization of Primary Isolates of HIV R. A. LaCasse, K. E. Follis, M. Trahey, J. D. Scarborough, D. R. Littman, J. H. Nunberg

Picking plankton in the 365 **Ross Sea**

- Isotopic Evidence for the Diet of an Early Hominid, Australopithecus africanus M. Sponheimer and J. A. Lee-Thorp
- ▼ 370 341 Ozone Isotope Enrichment: Isotopomer-**Specific Rate Coefficients** K. Mauersberger, B. Erbacher, D. Krankowsky, J. Günther, R. Nickel
 - 372 Self-Assembly of Ordered Microporous Materials from Rod-Coil Block Copolymers S. A. Jenekhe and X. L. Chen

SCIENCE'S COMPASS **EDITORIAL** 336 325 On the Frontiers of Science M. Cuénod LETTERS A vulnerable spot Transgenic Crops in Europe M. P. Gordon. 327 Edison and His Laboratory J. J. Gilman. Animal on HIV Rights J. E. R. Staddon; B. Coalgate and J. Coalgate; L. L. Davis; H. W. Hunt; C. A. Buckmaster; T. A. Shannon. Spanish Natural History Museum J. Garcia-Guinea and J. Martinez-Frias. Animal Domestication R. T. Loftus, D. E. MacHugh, P. ₹336 HIV VACCINES: Magic of the Occult? Cunningham, D. G. Bradley. Carbon Sink: A Clue from 357 D. C. Montefiori and J. P. Moore Biosphere 2? R. L. Walford. Corrections and Clarifications **POLICY FORUM** 338 **PLANETARY SCIENCE: Probing Europa's** Third Dimension C. R. Chapman MEDICINE: Physician-Scientists-331 Endangered and Essential L. E. Rosenberg ₹339 **NEUROSCIENCE: What Maintains** 381 Memories? J. E. Lisman and J. R. Fallon BOOKS ET AL. ANIMAL BEHAVIOR: If a Lion Could Talk 333 REVIEW Animal Intelligence and the Evolution of ATMOSPHERE SCIENCE: Mass-Independent 341 Consciousness S. Budiansky, reviewed by 370 **Isotope Effects in Planetary** D. Chenev Atmospheres and the Early Solar System 334 PLANT ECOLOGY: Seeds Ecology, M. H. Thiemens Biogeography, and Evolution of Dormancy **TECH.SIGHT** and Germination C. C. Baskin and J. M. Baskin, reviewed by S. J. Mazer MICROFLUIDICS: Microfluidic Diffusion-346 **Based Separation and Detection** PERSPECTIVES B. H. Weigl and P. Yager **335 BIOGEOCHEMISTRY: You Are What You Eat** 348 TechSightings M. J. Kohn 368

306

- 375 **Electron Transfer Between Bases in** Double Helical DNA S. O. Kelley and J. K. Barton
- **Emergent Properties of Networks of ▼381**339 Biological Signaling Pathways U. S. Bhalla and R. Iyengar
 - 387 Role of DNA 5-Methylcytosine Transferase in Cell Transformation by fos A.V. Bakin and T. Curran
 - 390 Xid-Like Immunodeficiency in Mice with Disruption of the p85 α Subunit of Phosphoinositide 3-Kinase H. Suzuki, Y. Terauchi, M. Fujiwara, S. Aizawa, Y. Yazaki, T. Kadowaki, S. Koyasu
 - 393 Impaired B Cell Development and Proliferation in Absence of Phosphoinositide 3-Kinase p85 α D. A. Fruman, S. B. Snapper, C. M. Yballe, L. Davidson, J. Y. Yu, F. W. Alt, L. C. Cantley

- **▼** 397 Role of Serotonin in the Paradoxical Calming Effect of Psychostimulants on Hyperactivity R. R. Gainetdinov, W. C. Wetsel, S. R. Jones, E. D. Levin, M. Jaber, M. G. Caron
 - 401 Unresponsiveness to Cannabinoids and **Reduced Addictive Effects of Opiates in** CB1 Receptor Knockout Mice C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.-F. Aubert, F. Beslot, G. A. Böhme, A. Imperato, T. Pedrazzini, B. P. Roques, G. Vassart, W. Fratta, M. Parmentier
 - 404 **Diminishing Returns from Mutation** Supply Rate in Asexual Populations J. A. G. M. de Visser, C. W. Zeyl, P. J. Gerrish, J. L. Blanchard, R. E. Lenski

TECHNICAL COMMENTS

Investigating the Possible Use of Fire at Zhoukoudian, China X. Wu. Response S. Weiner, Q. Xu, P. Goldberg, J. Liu, O. Bar-Yosef

www.sciencemag.org/cgi/content/full/283/5400/299a



THE JOURNAL www.sciencemag.org

SCIENCENOW DAILY NEWS SERVICE www.sciencenow.org

NEXT WAVE WEEKLY CAREER UPDATES www.nextwave.org

GRANTSNET RESEARCH FUNDING DATABASE www.grantsnet.org

NEUROAIDS EXPERIMENTAL WEB SITE www.sciencemag.org/NAIDS



375 Running the bases in DNA electron transfer

Change of address: allow 4 weeks, giving old and new addresses and 8-digit account number. Postmaster: Send change of address to Science, P.O. Box 1811, Danbury, CT 06813–1811. Single copy sales: \$8.00 per issue prepaid includes surface postage; bulk rates on request. Authorization to photo-copy material for internal or personal use under circumstances not falling within the fair use provisions of the Copyright Act is granted by AAAS to libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that 54.00 per article is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923. The identification code for Science is 0036-8075/83 \$4.00. Science is indexed in the Reader's Guide to Periodical Literature and in several specialized indexes

Simple isn't it. We know it isn't. Not when you are facing thousands of possible new drug leads and stretched R&D budgets.

Our job is to facilitate the business of bringing new therapies to market faster and more cost-effectively. If that's the business you're in, you'll find us at the very heart of it – discovering, developing and delivering the special technologies and support services – from research through to production.

Our know-how spans the entire pipeline from gene to medicine. Right now, our MegaBACE[™] DNA sequencing technology is accelerating the genome discovery race. LEADseeker[™] homogeneous imaging system can shorten a drug screening cycle five fold. STREAMLINE[™] technology delivers pure protein by the tonne.

And we continue to develop our contribution with highperformance systems for protein characterisation and exciting new miniaturisation techniques.

We understand your requirements because we work closely with our customers to provide the latest systems to accelerate their commercial success. We already have more than 70 such technology collaborations with top life science companies. The shared experience gives birth to new leading-edge technologies that match actual needs – and the discover, develop, deliver cycle can continue.

So it doesn't matter where you are in the process or how complex the task. Just ask us. It's that simple.

Discover more at www.apbiotech.com

Discover. Develop. Deliver.

Amersham Pharmacia Botech UK Limited Amersham Place, Little Chaffort, Bucklanghamshire, England HP? DNA-All goods and services are sold advect to the terms and conditions of sale of the company within the Amersham Pharmacia Biotech group which supplies them. A copy of here it terms and conditions of sale is available on request their terms and conditions of sale is available on request



Circle No. 30 on Readers' Service Card



Transformation in a snap.



Thaw. Add DNA. Heat shock. Plate. (Tbat's it.)

No screw caps. No dispensing. No freeze/thaw. No waste. No foul &-ME smells!

SINGLES Single aliquot competent cells. Now available for NovaBlue and pET host strains BL21(DE3) and BL21(DE3)pLysS.

For more information, phone: 800.526.7319 (US & Canada) • 0800-6931-000 (Germany call Calbiochem-NocaBiochem GmbH) • 0800-622935 (UK call CalBiochem-NocaBiochem visit our web site: www.novagen.com • send e-mail: novatech@novagen.com

International Distributors

Australia—Progen Industries I.d. 7-3375-1888 Austria—Bio-Trade 1-889-1819 Belgium—Euro Biochem scr1 10-43-70-60 Denmark—Bie&Bernisen A-S 44-94-88-22 Finland—Ya-Kemia 0y 9-350-3250 France—TEBU 130-46-3900 India—BioBusiness Development Agency 559-6820

Israel—Megapharm 9-904596 Italy—M-Medical 55-500-1871 Japan—Takara Shuzo Co., Ltd. 77-543-7231 Korea—B0HAN Biomedical 2-577-2002 Netberkands—Omnilabo International BV 76-5795-795 New Zealand—Interned Scientific Ltd. 9-443-1284

Norway—Bio-Test AS 22-619-660 Spain—bioNova cientifica, sl. 91-551-5403 Sweden—Labkemi AB 8-742-4200 Switzerland—Juro Supply AG 41-226-20-60 Taiwan—PROTECI 22-3810844 UK—CalBiochem-NovaBiochem (UK) Ld.0800-622935 Cambridge Bioscience 1223-316855

Circle No. 39 on Readers' Service Card



THIS WEEK IN SCIENCE edited by PHIL SZUROMI

MASS-INDEPENDENT ISOTOPE FRACTIONATION

Exchange of isotopes as part of a chemical process (reaction or diffusion) almost always reflects the relative masses of the isotopes involved. However, several gases-notably ozone, carbon dioxide, nitrous oxide, and carbon monoxide-and some meteorite grains and minerals seem to preserve a mass-independent relation among the isotopes. As discussed by Thiemens (p. 341) in a review, this effect can be used as a tracer or to provide information on the origins or sources and sinks of the gases, even though the mechanism responsible for the mass-independent fraction may remain obscure. One example of such an effect is the enrichment in the atmosphere of the heavier isotopes (¹⁷O and ¹⁸O) in ozone relative to the background levels. Asymmetric molecules (such as ¹⁶O¹⁷O¹⁸O) carry the highest enrichments, whereas symmetric molecules (such as ¹⁷O¹⁷O¹⁷O) are slightly depleted. Most explanations for this observation invoke kinetic effects induced by molecular symmetry. Mauersberger et al. (p. 370) now report rate coefficients for a range of ozone selection channels with different isotopic compositions. The results suggest that the collision process itself, rather than molecular symmetry, determines the enrichment.

NEUTRAL HYDROGEN ON IO

Io, Jupiter's closest large satellite, creates an enigmatic oxygen- and sulfur-rich plasma torus around Jupiter through the satellite's active volcanism and interaction with Jupiter's strong magnetic field. Roesler et al. (p. 353) used the Hubble space telescope imaging spectrograph to obtain far-ultraviolet images of neutral oxygen, sulfur, and hydrogen Lyman- α emission of lo's extended atmosphere. The temporal and spatial variations of the oxygen and sulfur suggest that volcanic emissions must be altered or accelerated by the jovian magnetic field, the plasma torus, or both. The hydrogen signal localized near each pole of Io was unexpected and may be produced by hydrogen-rich polar frost, dissociation of hydrogen concentrated at the poles by the jovian magnetic field, or reflection of the solar hydrogen Lyman- α radiation from lo's surface.

STILL WATERS FIX LEAST

One commonly predicted effect of climate change induced by greenhouse gases is an increase in the stratification of the Southern Ocean, a major area of primary production. Arrigo *et al.* (p. 365) show that this change may further hinder the ability of the plankton communities to decrease atmospheric CO_2 by fixation. Their studies of the plankton dynamics in the Ross Sea off Antarctica show that diatoms (which form silicate, not carbonate bodies) dominate in highly stratified waters, whereas *Phaeocystis antarctica* assemblage, which consume a much greater amount of CO_2 , dominate in mixed regions.

ORDERED POROUS POLYMERS

Unusual morphologies often result when two different polymer types are joined in one molecule. Rod-coil diblock copolymer, for example, join a rigid polymer based on conjugated monomers (such as polyphenylquinoline, PPQ) with a flexible polymer that forms coils (such as polystyrene, PS).



Jenekhe and Chen (p. 372) show that PPQ-PS diblock copolymers, when placed in solvent (carbon disulfide) that dissolves only the flexible coil, form micelles with diameters of a few micrometers. Solvent evaporation produces a well-ordered porous material that may have several applications, including use as a photonic band gap material.

AN OMNIVOROUS HOMINID?

Early hominids were thought to forage mainly in wooded areas for fruits and C_3 plants (for example, trees, bushes, and herbs). Sponheimer and Lee-Thorp (p. 368; see the Perspective by Kohn and the news story by Vogel) present carbon isotopic evidence from the enamel of teeth from *Australopithecus africanus*, which suggests that this 3-million-year-old ancestor ate more than fruits and leaves. The enamel shows enrichment in ¹³C consistent with a diet that includes C_4 plants (for example, grasses and sedges) found in more open grasslands, animals that consumed C_4 plants, or both. Thus, *A. africanus* may have had a more diverse diet that included ranging into open grasslands or preying on small, vulnerable mammals without the apparent use of any tools.

INTERBASE ELECTRON TRANSFER IN DNA

Studies of electron transfer through DNA have produced conflicting results, from ultrafast "molecular wire" behavior over many base pairs [characterized by β values of 0.1 per angstrom (Å⁻¹) or less] to strongly distance-dependent transport more typical of proteins (β values nearer to 1 Å⁻¹). One confounding issue in several previous studies showing ultrafast behavior is that the donors and acceptors have been species intercalated into DNA. Kelley and Barton (p. 375) now study electron transfer in DNA molecules that incorporate fluorescent analogs of adenine $(1, N^6$ -ethenoadenine and 2-aminopurine). Electron transfer rates deduced from fluorescence quenching by guanine or deazaguanine bases yielded β values ranging from 0.1 to 1.0 Å⁻¹. They conclude that stacking interactions and reactant energetics strongly influence the distance dependence and that electrons are preferentially transported between bases on the same strand.

FREEZING EPITOPES FOR HIV-1 VACCINES

The initial interactions between the human immunodeficiency virus-type 1 (HIV-1) envelope protein gp120 and the host cell result in a series of conformational changes in the viral envelope that result in cell-virus fusion. LaCasse et al. (p. 357; see the Perspective by Montefiori and Moore) used formaldehyde fixation of cells expressing viral envelope protein co-cultured with cells expressing CD4 and the coreceptor CCR5 to capture an intermediate structure. This epitope complex, which has been "frozen" on the expressing cell, was used as an immunogen in a mouse model. Unlike the currently available recombinant gp120 vaccine candidates, the "fusion-intermediate" immunogen stimulated production of antibodies that neutralized a broad array of primary HIV-1 isolates.

PUTTING PATHWAYS TOGETHER

Although the biochemical signaling pathways through which cells respond to various stimuli have generally been elucidated as linear chains of reactions, such pathways interact to form a complex network. Bhalla and Iyengar (p. 381; see the Perspective by CONTINUED ON PAGE 299

THE LOUIS-JEANTET PRIZE FOR MEDICINE

The 1999 laureates are

Adrian P. BIRD

Institute of Cell and Molecular Biology, University of Edinburgh, United Kingdom for his work on DNA methylation and gene regulation

Herbert JÄCKLE

Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany for his work on developmental biology in Drosophila

Jean-Louis MANDEL

Institute of Genetics and Molecular and Cellular Biology, CNRS/INSERM, Strasbourg, France, for his work on human molecular genetics

The Louis-Jeantet Foundation for medicine awards the three laureates the global sum of CHF 2'100'000, equally divided between them.

The Louis-Jeantet Prize for medicine is not intended to honour past accomplishments but to encourage innovative research. Candidates must be engaged in basic or clinical biomedical research in the European countries members of the Council of Europe. The Prize is awarded each year to one to three researchers or research groups. Since its inception in 1986, the Prize has encouraged forty-four researchers.

Call for nominations

Nominations for the 2000 Louis-Jeantet Prize for medicine will be accepted until February 15, 1999. Candidates must be nominated by scientists, physicians or institutions having detailed knowledge of their research. Self-nominations are not accepted. Selection is made by the Science Committee of the Foundation.

Application forms and further information are obtainable from the Secretary of the Science Committee The Louis-Jeantet Foundation for medicine, P.O. Box 277, CH - 1211 GENEVA 17, Switzerland Tel. ++4122 704 36 36; Fax ++4122 704 36 37; Email: <u>info@jeantet.ch</u>; Home page: <u>www.jeantet.ch</u> Only original signed application forms will be considered.

The name(s) of the laureates of the 2000 Louis-Jeantet Prize for medicine will be announced in January 2000. The Prize Ceremony will take place in Geneva (Switzerland) in April 2000.

FONDATION LOUIS-JEANTET DE MÉDECINE

Circle No. 14 on Readers' Service Card

THIS WEEK IN SCIENCE

CONTINUED FROM PAGE 297

Lisman and Fallon) used computation methods to model networks that comprised up to four individual signaling pathways. All of the model parameters were derived from experiment. The results show that such networks can have properties not present in the individual pathways that may be critical for proper cellular regulation. Combinations of common signaling pathways showed, for example, the capacity to remain activated after an initial stimulus was removed and had specific requirements for the amplitude and duration of a signal to reach a threshold for activation. Such coordination may provide a mechanism for storing information.

CHANGE FOR THE BETTER

Mutations, generally deleterious and occasionally advantageous, provide the grist for adaptive evolution. De Visser *et al.* (p. 404) have investigated the complex relation between the rate at which new mutations arise and the course of adaptive evolution in bacterial populations evolving in the laboratory. In small or well-adapted populations, their evolution is limited by the rate at which they can produce new mutations. In large or poorly adapted populations, the rate of new mutations has little effect on the rate of evolution. Thus, a hypermutable phenotype can be advantageous in the right circumstances.

IMMUNE-DEFICIENCY LINK

Mice and humans who lack Bruton's tyrosine kinase (Btk) have an immunodeficiency that primarily affects B cell development and production of serum immunoglobulin. Suzuki *et al.* (p. 390) and Fruman *et al.* (p 393) generated mutant mice, or mice in which only lymphocytes were affected, that were deficient in the p85 α regulatory subunit from phosphoinositide-3 kinase (PI3K). These mice had a phenotype similar to that of the Btk deficient mice.

HYPERACTIVITY PARADOX

Psychostimulant drugs have been used for many years to treat children with attention-deficit hyperactivity disorders (ADHD). This therapy was introduced after empirical observations without an understanding of this paradoxical effect. Gainetdinov et al. (p. 397; see the news story by Marx) analyzed mice lacking the dopamine transporter gene. These animals showed striking similarities in their behavior to ADHD children and could also be calmed down by psychostimulants. The paradoxical effect depends on normal serotoninergic neurotransmission. These findings may serve as a useful model to develop new therapies to improve these widespread childhood behavioral defects.

CANNABIS, OPIATES, AND REWARD MECHANISMS

Much debate has centered around the linkage between cannabis use and subsequent use of opiates. Ledent et al. (p. 401) analyzed mutant mice that were lacking the central cannabinoid receptor CB1. These animals did not respond to any of the cannabis derivatives, and none of the typical CB1 receptor-mediated effects could be observed. Although opiates had no unexpected behavioral effect, mutant animals showed less addiction and also less severe withdrawal symptoms. It seems as if CB₁ receptors are involved in the manifestation of physical dependence in opiate addiction. This finding may further our understanding of the processes that lead to drug addiction and may also help to develop new strategies to combat drug addiction.

TECHNICAL COMMENT SUMMARIES

Investigating the Possible Use of Fire at Zhoukoudian, China

The full text of these comments can be seen at www.sciencemag.org/cgi/content/full/283/5400/299a

S. Weiner *et al.* (Reports, 10 July, p. 251) reexamined "the oldest reliable evidence for the controlled use of fire by humans" in Layer 10 at Zhoukoudian (the Peking Man site). They found "burned and unburned bones ... present in the same layer with stone tools," but "no ash or charcoal remnants." They concluded that there was only "indirect evidence for burning."

X. Wu comments that Weiner *et al.* "do not fully address the wealth of data collected at the entire site since the 1930s, and they do not adequately account for problems of material transport by water that apply to the particular sample they studied." He states that other studies do "show that fire was used in this site."

In response, S. Weiner *et al.* state that the "demonstration of free carbon" in earlier studies "does not necessarily imply that the organic matter was burned." They agree with Wu that there is "evidence in support of fire use" and that "many open questions" remain, but state that there is not "conclusive, direct evidence for the use of fire by *Homo erectus.*"

www.sciencemag.org SCIENCE VOL 283 15 JANUARY 1999

MEN: DNA Ligation, Cloning & Screening in 24 Hours!

Epicentre's new Fast-Link[™] DNA Ligation & Screening Kit greatly reduces the time necessary to clone DNA fragments and identify recombinants.

- Fast & Easy Ligation. DNA with restriction enzyme-generated cohesive or blunt ends are ligated in just 5 minutes. PCR products with 3' A-overhangs are ligated in 1 hour.
- Fast & Easy Screening. Using the exclusive Fast-Link In-Well Gel Screening reagents & protocol, colonies containing recombinant plasmids can be identified quickly without the need to grow cultures or perform minipreps.
- High Transformation Efficiencies. The Fast-Link Kit yields more transformants with a lower background.

Fast-Link [™] Representative Results.				
	Ligation Time	% White Colonies	Recombinants per µg DNA	
Overhang	5 min.	93	2.0 x 10 ⁶	
Blunt	5 min.	71	4.4 x 10 ⁵	
PCR product	1 hr.	68	1.2 x 104	

Call for further information on the Fast-Link Kit.

If you are not satisfied with any Epicentre product, we will refund your money.





...when you need to be sure of the quality

Outside of the U.S. contact the distributor in your country, or call 608-258-3080 or fax 608-258-3088. E-mail: techhelp@epicentre.com World Wide Web: http://www.epicentre.com

Circle No. 40 on Readers' Service Card

www.sciencemag.org

EDITOR-IN-CHIEF Floyd E. Bloom

EDITOR **Ellis Rubinstein**

MANAGING EDITOR Monica M. Bradford

EDITORIAL

DEPUTY EDITORS Philip H. Abelson (Engineering and Applied Sciences); John I. Brauman (Physical Sciences); Thomas R. Cech (Biological Sciences)

SENIOR EDITORS Gilbert J. Chin, R. Brooks Hanson, Pamela J. Hines, Barbara Jasny, Paula A. Kiberstis, Linda J. Miller, L. Bryan Ray, Phillip D. Szuromi; Associate Editors Beverly A. Purnell, Linda R. Rowan; EDITORIAL ASSISTANT Carolyn Kyle; MANUSCRIPT ASSIS-TANTS Candace Gallery, Amy Herda, Patricia M. Moore, Anita Wynn; ADMINISTRATIVE SUPPORT Sylvia Kihara

SCIENCE'S COMPASS: SENIOR EDITOR Katrina L. Kelner; ASSOCIATE BOOK REVIEW EDITOR Sherman J. Suter; CONTRIBUTING EDITORS David F. Voss, Kevin Ahern; Assistants Brent Gendleman, Jeffrey Hearn;

PUBLISHER **Richard S. Nicholson**

ASSOCIATE PUBLISHER **Beth Rosner**

MEMBERSHIP/CIRCULATION DIRECTOR Michael Spinella

MEMBERSHIP/CIRCULATION

DEPUTY DIRECTOR Marlene Zendell MEMBER SERVICES: MANAGER Michael Lung; SUPERVISOR Mary Curry; REPRESENTATIVES Laurie Baker, Pat Butler, Christine Ford, Mari Pope, Jantell Smith

MARKETING: MANAGER Scott Oser; coordinator Lauri Sirois; EUROPE MANAGER Jane Pennington; Associate Ruth Jackson RESEARCH: MANAGER Renuka Chander

BUSINESS AND FINANCE: MANAGER Dwight Theall; ASSISTANT SUSAN Maxim; COMPUTER SPECIALIST Charles Munson

FINANCE AND ADVERTISING

BUSINESS AND FINANCE: BUSINESS MANAGER Deborah Rivera-Wienhold; SENIOR ANALYST Randy Yi; FINANCIAL ANALYST LISA DONOVAN RIGHTS AND PERMISSIONS: ASSOCIATE LINCOLN RICHMAN; ASSISTANT Emilie David MARKETING: DIRECTOR John Meyers; Associates Allison Pritchard, Chris Harbaugh ELECTRONIC MEDIA: MANAGER David Gillikin; COMPUTER SPECIALIST Wendy Green; PRODUCTION ASSOCIATES Mark Croatti, Ellen McGuire

Adrienne E. Clarke University of Melbourne, Parkville

F. Fleming Crim University of Wisconsin, Madison Paul J. Crutzen Max-Planck-Institut für Chemie

James E. Dahlberg University of Wisconsin Medical School, Madison

National Institute of Mental

Swedish Univ. of Agricultural Sciences, Uppsala Paul T. Englund Johns Hopkins University

Robert Desimone

Health, NIH

School of Medicine

Richard G. Fairbanks

Jack F. Greenblatt

Max-Planck-Gesellschaft

Lamont-Doherty Earth Observatory

Douglas T. Fearon University of Cambridge Harry A. Fozzard

The University of Chicago

Roger I. M. Glass Centers for Disease Control Peter N. Goodfellow SmithKline Beecham, UK

University of Toronto Peter Gruss Max Planck Institute of Biophysical Chemistry

Hans Eklund

G. Ertl

Frederick W. Alt Children's Hospital, Boston

Michael Ashburner

Alan Bernstein

David E. Bloom

Henry R. Bourne

James J. Bull

Seth Blair

Piet Borst

Don L. Anderson California Institute of Technology

University of Cambridge Frank S. Bates Univ. of Minnesota, Minneapolis

Stephen J. Benkovic Pennsylvania State University

Mount Sinai Hospital, Toronto Michael J. Bevan University of Washington, Seattle

University of Wisconsin, Madison

The Netherlands Cancer Institute

Univ. of California, San Francisco

James J. Bull University of Texas at Austin Kathryn Calame Columbia Univ. College of Physicians & Surgeons

Dennis W. Choi Washington Univ. School of Medicine, St. Louis

Children's Hospital, Boston

Joanne Chory The Salk Institute David Clapham

Harvard Institute for International Development

INFORMATION SPECIALIST Janet Kegg

LETTERS AND TECHNICAL COMMENTS: EDITOR Christine Gilbert; Associate EDITOR Steven S. Lapham; ASSISTANT Charlene King

TECH.SIGHT: CONTRIBUTING EDITORS RICHARD PETERS, ROBERT SIKORSKI EDITING AND PROOFREADING: DIRECTOR DAWN MCCOY; SUPERVISOR Cara Tate; SENIOR COPY EDITORS Cay Butler, Harry Jach, Barbara Ordway, Christine M. Pearce; COPY EDITORS: Jeffrey E. Cook, Etta Kavanagh, Jason Llewellyn, Joshua Marcy

COPY DESK: Joi S. Granger, Monique Martineau, Ellen E. Murphy, **Beverly Shields**

News

NEWS EDITOR Colin Norman; FEATURES EDITOR TIM Appenzeller; DEPUTY NEWS EDITORS Elizabeth Culotta (contributing editor), Jean Marx, Jeffrey Mervis, Richard Stone; NEWS WRITERS Michael Hagmann (intern), Constance Holden, Jocelyn Kaiser, Richard A. Kerr, David Kestenbaum, Andrew Lawler, David Malakoff, Eliot Marshall, Elizabeth Pennisi, Robert F. Service, Gretchen Vogel BUREAUS: BERKELEY, CA Marcia Barinaga (contributing correspondent); SAN DIEGO, CA JON Cohen; CHICAGO, IL James Glanz; COPY EDITORS Linda B. Felaco, Daniel T. Helgerman; CONTRIBUTING CORRESPONDENTS Barry A. Cipra, Ann Gibbons, Charles C. Mann, Anne Simon Moffat, Virginia Morell, Evelyn Strauss, Gary Taubes, Ingrid Wickelgren; ADMINISTRATIVE SUPPORT Scherraine Mack, Fannie Groom

PRODUCTION

DIRECTOR James Landry; MANAGER Wendy K. Shank; Assistant MANAGER Lizabeth A. Harman; Associates Vicki J. Jorgensen, Tara L. Kelly, Jessica K. Moshell, Rebecca Thomas

PRODUCT ADVERTISING

NATIONAL SALES MANAGER NORTHEAST AND E. CANADA Richard Teeling: 973-904-9774, FAX 973-904-9701 · MIDWEST/ SOUTHEAST Elizabeth Mosko: 773-665-1150, FAX 773-665-2129 • west COAST/W. CANADA Neil Boylan: 415-673-9265, FAX 415-673-9267 • MID ATLANTIC AND U.S. INSIDE SALES Christopher Breslin: 202-326-6544, FAX 202-682-0816 · INTERNET SALES LAURA Tellez 202-326-6599, FAX 202-682-0816 UK/SCANDINAVIA/FRANCE/ ITALY/BELGIUM/NETHERLANDS Andrew Davies: (44) 7071-226-216, FAX (44) 7071-226-233 · GERMANY/SWITZERLAND/AUSTRIA Tracey Peers: (44) 1-260-297-530, FAX (44) 1-260-271-022 JAPAN Mashy Yoshikawa: (81) 3-3235-5961, FAX (81) 3-3235-5852 • TRAFFIC MANAGER Carol Maddox; SALES ASSOCIATES Sheila Myers, Sandra Walls; ADMINISTRATIVE SUPPORT JESSICA Tierney

RECRUITMENT ADVERTISING

SALES AND PRODUCTION OPERATIONS MANAGER TERTI Seiter Azie U.S.: SALES MANAGER Gabrielle Boguslawski: 718-491-1607, FAX 202-289-6742; SALES SUPERVISOR Daryl Anderson; SALES REPRESENTATIVES Troy Benitez, Beth Dwyer, Bren Peters-Minnis, Kristin Westapher; ASSISTANTS Erika Bryant, Kathleen Clark; Christina Geiger PRODUCTION: SENIOR ASSOCIATE Jennifer Rankin; ASSOCIATE Elizabeth LENOX COPY EDITOR/PROOFREADER Chris Filiatreau U.K./EUROPE: SALES MANAGER Debbie Cummings; SALES EXECUTIVE Sabine Lenud; ASSIS-TANT Elisabeth Py: (44) 1-223-326-500, FAX (44) 1-223-326-532 AUSTRALIA/NEW ZEALAND: Keith Sandell: (61) 02-9922-2977, FAX (61) 02-9922-1100 JAPAN: Mashy Yoshikawa: (81) 3-3235-5961, FAX (81) 3-3235-5852

BOARD OF REVIEWING EDITORS

Philip C. Hanawalt Stanford University Paul Harvey University of Oxford M. P. Hassell Imperial College at Silwood Park Nobutaka Hiroka University of Tokyo Tomas Hökfelt Karolinska Institutet Tasuku Honjo Kyoto University Susan D. Iversen University of Oxford Eric F. Johnson The Scripps Research Institute Hans Kende Michigan State University Elliott Kieff Harvard University National Center for Atmospheric Research, Boulde University of Wisconsin, Madison Stephen M. Kosslyn Harvard University Michael LaBarbera The University of Chicago Antonio Lanzavecchia Basel Institute for Immuno unology Nicole Le Douarin Institut d'Embryologie Cellulaire et Moléculaire du CNRS Norman L. Letvin Beth Israel Hospital, Boston

Harvey F. Lodish Whitehead Institute for Biomedical Research Richard Losick Richard Losick Harvard University Seth Marder California Institute of Technology Diane Mathis Institut de Chimie Biologique, Strasbourg Susan K. McConnell Stanford University Anthony R. Means Duke University Medical Center Stanley Meizel Stanley Meizel University of California, Davis Douglas A. Melton Harvard University Andrew Murray Univ. of California, San Francisco Elizabeth G. Nabel The Univ. of Michigan Medical Center Shigetada Nakanishi Kyoto University Kim Nasmyth Research Institute of Roger A. Nicoll Univ. of California, San Francisco

Kyoto University

Bert W. O'Malley Baylor College of Medicine Roy R. Parker коу к. Yarker University of Arizona, Tucson Stuart L. Pimm The Univ. of Tennessee, Knoxville Yeshayau Pocker Univ. of Washington, Seattle Martin Patt Martin Raff University College London Douglas C. Rees California Institute of Technology T. M. Rice ETH-Hönggerberg, Zürich David C. Rubie Universität Bayreuth Erkki Ruoslahti The Burnham Institute. CA Gottfried Schatz Biozentrum, Basel Jozef Schell Max-Planck-Institut für Zuchtungforschung Ronald H. Schwartz National Institute of Allergy and Infectious Diseases, NIH Terrence J. Sejnowski The Salk Institute Christopher R. Some rville Christopher R. Somerville Carnegie Institute of Washing-ton, Stanford, CA Michael P. Stryker Univ. of California, San Francisco Cliff Tabin Harvard Medical School John Jan Ta John Jen Tai National Taiwan University

Tomoyuki Takahashi University of Tokyo Masatoshi Takeichi Masatoshi Takeichi Kyoto University Kejij Tanaka RIKEN Institute David Tilman Univ. of Minnesota, St. Paul Robert T. N. Tjian University of Tokura University of Tokyo Derek van der Kooy University of Toronto Geerat J. Vermeij University of Toronto Geerat J. Vermeij University of California, Davis Bert Vogelstein Johns Hopkins Oncology Center Gerhard Wegner Center ' Gerhard Wegner Max-Planck-Institut für Polymerforschung Arthur Weiss Univ. of California, San Francisco Zena Werb Univ. of California, San Francisco George M. Whitesides Hanoard University Harvard University Ian A. Wilson The Scripps Research Institute Alan P. Wolffe National Institute of Child Health and Human Development, NIH

Martin Zatz National Institute of Mental Health, NIH

ART

DESIGN DIRECTOR AMY DECKER HENRY; ART DIRECTOR C. Faber Smith; Associate ART DIRECTOR Elizabeth Carroll; SCIENTIFIC IL-LUSTRATOR Katharine Sutliff; GRAPHICS ASSOCIATES Holly Bishop, Preston Morrighan, Darcel Pugh, Patricia M. Riehn; PHO-TO RESEARCHER Leslie Blizard

SCIENCE INTERNATIONAL EUROPE

EDITORIAL: OFFICE HEAD AND SENIOR EDITOR Richard B. Gallagher; ASSOCIATE EDITORS Stella M. Hurtley, Ian S. Osborne, Peter Stern, Julia Uppenbrink; EDITORIAL ASSOCIATE Belinda Holden NEWS: EDITOR Daniel Clery; CONTRIBUTING CORRESPONDENTS Michael Balter (Paris); Robert Koenig (Bern); UK EDITOR, SCI-ENCE'S NEXT WAVE John MacFarlane; ADMINISTRATIVE SUPPORT Janet Mumford, Liz Ellis

ASIA

JAPAN NEWS BUREAU: Dennis Normile (contributing correspondent); CHINA REPRESENTATIVE HAO XIN; INDIA CORRESPONDENT Pallava Bagla (contributing)

SCIENCENOW: www.sciencenow.org EDITOR Erik Stokstad

SCIENCE'S NEXT WAVE: www.nextwave.org

MANAGING EDITOR Wendy Yee; SENIOR EDITOR Nicole Ruediger writ-ER Melissa Mertl; CANADA EDITOR Charles Boulakia; Assistant Suzanne Moore

AAAS BOARD OF DIRECTORS

RETIRING PRESIDENT, CHAIR Mildred S. Dresselhaus PRESIDENT M. R. C. Greenwood PRESIDENT-ELECT Stephen Jay Gould TREASURER William T. Golden EXECUTIVE OFFICER Richard S. Nicholson

Robert D. Goldman; Alice S. Huang; Sheila Jasanoff; Sally Gregory Kohlstedt; Marcia C. Linn; Michael J. Novacek; Neena B. Schwartz; Jean E. Taylor

Published by the American Association for the Advancement of Science (AAAS), Science serves its readers as a forum for the presenta tion and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in Science-including editorials, news and comment, and book reviews-are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.



Finally, a transfection reagent that makes you smile, every time!

Introducing GenePORTER[™] Transfection Reagent[™]

GenePORTER[™] reagent, which incorporates direct hydrophilic conjugation (DHC) technology^{*}, is the latest innovation from the lab of Dr. Philip Felgner, inventor of lipofection. We at Gene Therapy Systems are so confident as to the performance of our product, we stand behind it with a double-your-satisfaction guarantee⁺ on cell types listed. In a variety of cell lines, GenePORTER reagent consistently delivers higher levels of transfection than any other commercially available product. Without compromising transfection efficiency, this robust reagent performs in a wide range of conditions, including different ratios of plasmid and reagent. GenePORTER reagent is easy to use and does not require enhancers or special handling of cells, saving time, cost, and reagents. Order GenePORTER reagent today. The results will make you smile.

GenePORTER[™] Iransfection Reagent

75 reactions • T201007 150 reactions • T201015 750 reactions • T201075



To Order: 888-428-0558 Fax: 619-587-1499

10190 Telesis Court San Diego, CA 92121, USA For the complete product list check out the GTS Website @ http://www.genetherapysystems.com



The β -Gal encoding plasmid was delivered into cells using GenePORTER and competitor's transfection reagents. Each manufacturers protocol was followed. β -Gal expression was measured 48 hours after transfection by a colorimetric assay.

Transfected Cell Types[†] * Patents pending

HeLa S3 BHK-21 293 CHO-K1 Jurkat CV-1 NIH 3T3 COS-1 B16-F0 COS-7 PC-12 If you do not get better transfection results following our protocol, kit purchase price will be refunded or double-the-kit price will be applied to your GTS, Inc. account toward future purchases. Offer valid in USA only and ends 1/31/99. Guarantee is limited to cell types in this ad. The purchased GenePORTER reagent must be returned using the GTS, Inc. return policy. This offer is limited to one T201007 or T201015 kit per customer.

Circle No. 41 on Readers' Service Card

GTS International Distributors

Australia • ASTRAL +61-2-9540-2055 Austria • BIO-TRADE +43 1 889 18 19 Denmark, Finland, Norway, Sweden • KEBO Lab +46 8 621 35 07 France • OZYME +1 30 85 92 92 Germany • Biozym Diagnostik GmbH +49 5152-9020 Japan, Rep. of China, Korea • Takara +81-77-543-7231 Switzerland • Axon Lab AG +41 56 484 80 80 Taiwan • PROtech, Ltd. 886-2-23810844 Takara +81-77-543-7231 United Kingdom • Lifescreen LTD. +44 0 1923 241515

NEW ENGLAND BIOLABS

finally

the end of primer walking, random subcloning and nested deletions



choose GPS[™]-1 Genome Priming System and complete your sequencing project in no time.

New England Biolabs introduces GPS-1, a fast, *in vitro* Tn7 transposon-based method for generating a population of DNA sequencing templates containing primer-binding sites (Transprimer element) at randomly interspersed positions. Simply supply your DNA of interest (0.08 μ g per 20 μ l reaction mix), follow a short protocol, transform into *E. coli*, miniprep colonies and then sequence.

- Transprimer is inserted randomly into the target DNA: no "hot spots" for insertion
- High efficiency: 10³-10⁵ insertion products recovered per reaction; entire protocol takes less than 90 minutes
- Unique rare-cutting restriction enzyme sites within Transprimer facilitate insert mapping
- DNA sequence can be obtained from both strands of target DNA using supplied primers
- Faster than primer walking, random subcloning and nested deletion methods

GPS-1 Genome Priming System

#7100 10 reactions Special Introductory Price until 3/1/99

Includes: pGPS1 (Kan¹) and pGPS2 (Cam¹) Transprimer donor plasmids, TnsABC* Transposase, control target plasmid, sequencing primers for the two ends of the Transprimer, buffers and instruction manual.

Transprimer is inserted randomly into the target DNA, generating a set of insertion products with only one Transprimer per molecule.

- For further information on GPS-1, visit www.neb.com or call 1-800-NEB-LABS
- New England Biolabs Inc. 32 Tozer Road, Beverly, MA 01915 USA 1-800-NEB-LABS Tel. (978) 927-5054 Fax (978) 921-1350 email: info@neb.com
- New England Biolabs Ltd., Canada Tel. (800) 387-1095 (905) 672-3370 Fax (905) 672-3414 email: info@ca.neb.com
- New England Biolabs GmbH, Federal Republic of Germany Tel. 0800/BI0LABS (06196) 3031 Fax (06196) 83639 email: info@de.neb.com
- New England Biolabs (UK) Ltd. Tel. (0800) 31 84 86 (01462) 420616 Fax (01462) 421057 email: info@uk.neb.com

BioLabs inc.

DISTRIBUTORS: Australia (07) 5594-0299; Belgium (0800)1 9815; Brazil (011) 366-3565; Denmark (39) 56 20 00; Finland (9) 584-121; France (1) 34 60 24 24; Greece (01) 5226547; Hong Kong 2649-9988; India (542) 311473; Israel (03) 9229013; Italy (02) 381951; Japan (03) 5820-9408; Korea (02) 556-0311; Mexico (5) 280-5691; Netherlands (033) 495 00 94; New Zealand 0800 807809; Norway 22 09 15 00; Singapore 4457927; Spain (03) 902 20 30 90; Sweden (08) 30 60 10; Switzerland (061) 486 80 80; Taiwan (02) 28802913

Circle No. 38 on Readers' Service Card

Research –



Less Search.

Purchase Your Biological and Chemical Reagents.

Faster. Easier. Online.

Search less to find the reagents you need and discover more of what you're looking for—at chemdex.com. Register for a free password today and experience the future.

www.chemdex.com



chemdex.com

Search less. Discover more.

© 1998 Chemdex Corporation. Chemdex is a registered trademark of Chemdex Corporation.

Circle No. 15 on Readers' Service Card



Serum-Free and Low Serum Media

Innovative Cell Systems, Since 1986 for Research in:

 Cell Therapy Tissue Replacement Degenerative Disease

xcellence.

- High Throughput Screening
- Toxicology

enal Cell Systen

Cell Biology

Providing the Best In-Vitro Models

- Relevant Non Transformed Human Cells
- Optimized Culture Systems Matching Cells and Medium

Custom Cell

BIOX WHITTAKER

A CAMBREX Company

- Low Serum and Serum-Free Media
- Standardized/Quality Controlled Products GMP Manufacturing Available
- The Leading Research Team in Human Cell System Development

BioWhittaker is a certified ISO-9001 Quality Management System Company

UK: 011 8 979 5324 • Europe: 32 87 32 16 11 • USA, Canada and all other: 301 898 7025

©1998 BioWhittaker, Inc., A Cambrex Company. The symbols ® and ™ refer to trademarks in the U.S.A. and other countries. All rights reserved. Vestern Blots of Clonetics Cells • Custom Cell Isolations • Ancyte™ Animal Cell Syst Circle No. 28 on Readers' Service Card

NEW TR717[™] Luminometer

a measure of Illance

Introducing the new TR717 Microplate Luminometer from Tropix. Now you can enhance your efforts with ultrasensitive detection of bioanalytes from the leader in luminescence. Only Tropix brings you a full line of matched luminescent reagents, assays and instrumentation designed for optimal performance in your lab.

SENSITIVE.

Achieve low zeptomole* detection levels with advanced digital photon counting.

FLEXIBLE.

Command a unique constellation of features for superior versatility in applications and protocol design.

- Read 96- or 384-well plates
- Detect wide range of analyte concentration (>7 decades)
- High functionality with or without external PC
- Programmable reagent dispensers available
- Robotics-compatible
- Temperature control option

To request a free TR717 Luminometer brochure or to learn more about Tropix reagents and systems, call **1-800-542-2369**.

TROPIX

TROPIX

47 Wiggins Avenue Bedford, Massachusetts 01730 USA Tel: 781-271-0045 800-542-2369 Fax: 781-275-8581 E-mail: info@tropix.com

PE APPLIED BIOSYSTEMS

USA Foster City, CA Tel: 800-345-5224 650-570-6667 Fax: 650-638-5884

Europe Langen, Germany Tel: 49 6103 708 301 Fax: 49 6103 708 310 Canada Mississauga, Ontario Tel: 800-668-6913 905-821-8183 Fax: 905-821-8246

Japan Chiba Tel: (0473) 80-8500 Fax: (0473) 80-8505 *Latin America* Mexico City, Mexico Tel: 52-5-651-7077 Fax: 52-5-593-6223

Australia Victoria Tel: (03) 9212-8585 Fax: (03) 9212-8502

Tropix is a registered trademark and TR717 is a trademark of Tropix, Inc. PE Applied Biosystems is a trademark of the Perkin-Elmer Corporation. ©1997 Tropix, Inc. All rights reserved. Printed in USA.

PE Applied Biosystems

Circle No. 26 on Readers' Service Card

This is your life's work. What's it worth?

If it's worth saving, it's worth saving in a Revco, now with Legaci™, our time-tested combination of custom built Copeland compressors and DuPont Suva® refrigerants .



Legaci™ represents years of research, life testing and quality assurance. For ultra-low storage of high value materials, you need reliability, stability and dependability, no compromise. That's why Revco has developed *Legaci*™, a refrigeration system created exclusively for life science, pharmaceutical and laboratory applications.

Legaci[™] represents a collaborative effort between Revco and the world's leading compressor and refrigerant manufacturers, Copeland and DuPont. Together, we've life tested new compressor hardware and refrigerant chemistry which, combined,

Powered by

deliver the highest reliability coefficients ever offered. Before you buy an ultra-low freezer, learn more about *Legaci*™.

When it comes to your work and our freezers, it's what's inside that counts.

800-252-7100 www.revco-sci.com/legaci

and upright models to -86°C



275 Aiken Road, Asheville, NC 28804 www.revco-sci.com USA 800-252-7100 Canada 800-447-3826 International 828-658-2711 Fax 828-645-3368

Topeland DuPont Suva®Refrigerants

Circle No. 35 on Readers' Service Card

FOR the EDUCATION and RESEARCH COMMUNIT

HELPING YOU BUILD A SECURE FINANCIAL FUTURE IS AN IMPORTANT JOB. FORTUNATELY,

TIAA-CREF HAS THE PERFECT RESUME.

With 80 years of leadership experience in our field, TIAA-CREF is eminently qualified to help you build a comfortable, worryfree retirement.

Our references are equally impeccable today, two million of the best minds in America trust us with their retirement plans, turn to us for mutual funds and their insurance needs. Allow us to review our qualifications.

Superior strength

With \$200 billion in assets, TIAA-CREF is the world's largest retirement organization—and among the most solid. TIAA is one of only a handful of companies to have earned top ratings for financial strength, and CREF is one of Wall Street's largest investors.¹

Solid, long-term performance

We seek out long-term opportunities that other companies, in pursuit of quick gains, often miss. Though past performance can't guarantee future results, this patient philosophy has proven extremely rewarding.

Surprisingly low expenses

TIAA-CREF's operating costs are among the lowest in the insurance and mutual fund industries.² Therefore, more of your money goes where it should—towards ensuring your future.

Easy diversification

We offer a wide variety of expertly managed investment options to help build your assets. With stock, bond, money market, and real estate accounts to choose from —as well as a guaranteed annuity — TIAA-CREF makes diversification easy.

Unrivaled service

We believe that our service distinguishes us from every other retirement company. In a recent nationwide survey of retirement plans, TIAA-CREF was voted number one in participant satisfaction.³

If you work in education, research, or related fields, why not put TIAA-CREF's experience to work for you? To find out more, visit our Web site at www.tiaa-cref.org or call us at 1 800 842-2776.

12/98



Ensuring the future for those who shape it.[™]

¹A++ (Saperior). A.M. Best Co.; AAA. Duff & Phelps: Asa, Moody's Investors Services; AAA, Standard and Poor's for stability, sound investments, claims-paying ability, and overall financial strength. These ratings of TIAA as an insurance company do not apply to CREF or the TIAA Real Estate Account. *Standard & Paeri Juanure Rating Audjusi*, 1999; Lipper Analytical Services. Inc., *Lipper Directori Audylicia Units*, 1998 (Quartely). ¹DALBAR, Inc., 1997 Defined Curribulian Excellence Ratings. For more complete information, including charges and expenses, call 1800 84:2-2733, extension 5509, for CREF and TIAA Real Estate Account prospectuses. Read them carefully before you invest or send money. TIAA-CREF Individual and Institutional Services, Inc. distributes CREF certificates and interests in the TIAA Real Estate Account.



Circle No. 18 on Readers' Service Card



Make the Move To 384-Well Non-Isotopic Assays!

Make the move to Packard's FluoroCount[®] and LumiCount[®] for your fluorescent and luminescent applications. Now capable of 384-well measurements!

FluoroCount Fluorescence Detection

- Now even more flexible with 6-, 12-, 24-, 48-, 96- and 384-well measurements
- Top and bottom reading capabilities
- External excitation source provides ultra sensitivity
- UV excitation down to 260 nm!

LumiCount Luminescence Detection

- Glow applications in 96- and now, 384-well formats
- Excellent sensitivity with unique Digital Photon Integration (DPI)
- Internal temperature control from ambient +5 °C to 45 °C for cell cultures

The best value in microplate counters just got better!



Packard Instrument Company

800 Research Parkway Meriden, CT 06450 U.S.A. Tel: 203-238-2351 Toll Free: 1-800-323-1891 FAX: 203-639-2172 Web Site: http://www.packardinst.com Ernail: webmaster@packardinst.com

Packard International Offices:

Australia 03-9543-4266 or 1 800 335 638; Austria 43-1-2702504; Belgium 32(0)2/481.85.30; Canada 1-800-387-9559; Central Europe 43 456 2220 015; Denmark 45-43909023 or 45-43907151; France (33) 1 46.86.27.75; Germany (49) 6103 385-151; Italy 39-2-33910796; Japan 81-3-3866-5850; Netherlands 31-50-549 1296; Russia 7-095-259-9632; Switzerland (01) 481 69 44; United Kingdom 44 (0)118 9844981

Detection Technology Begins and Ends With



KPL introduces our new line of Detector[™] Kits that provide you with fast, sensitive detection without radioactivity!

COOL ASSAYS

RNADetector[™] **Northern** Non-isotopic Northern blot that rivals³² P

DNADetector [™] Southern Chemiluminescent detection of Southern blots and colony lifts

DNADetector[™] *In Situ* Fluorescent and chromagenic *in situ* hybridization systems

ExpressDetector[™] Nickel-HRP Direct detection of recombinant his-tagged proteins

Protein Detector ™ Chromagenic and chemiluminescent Western blot and ELISA systems

HOT RESULTS





 Sensitivity equivalent to radioactivity in a fraction of the time

 Complete kits reduce preparation and optimization time

SPECIAL OFFER:

Celebrate our 20th anniversary and receive 20% off when you purchase any of the Detector[™] kits listed here. First time orders only. Call 1-800-638-3167 (U.S.) or 301-948-7755 for more information and a free catalog.

egaard & Perry



20 Years of Detection Expertise

2 Cessna Ct., Gaithersburg, MD 20879-4174, U.S.A. 800-638-3167 (U.S.) or 301-948-7755 Fax: 301-948-0169 www.kpl.com Circle No. 22 on Readers' Service Card





Request for Proposals

High-throughput Screening and Combinatorial Chemistry Approaches for Cystic Fibrosis Drug Discovery

Application Receipt Date: Open

Developments in the understanding of the cystic fibrosis (CF) basic defect and the role of the CF gene product, CFTR, have enabled scientists to develop strategies for new therapies. The Cystic Fibrosis Foundation (CFF) is soliciting proposals to utilize the growing body of knowledge about CF to develop systems that rapidly discover chemical compounds which correct the function of CF cells. This will be achieved by using the technologies of high-throughput screening (HTS) and combinatorial chemistry (CC).

The CFF will consider proposals for review that address the following issues, but are not limited to:

- developing miniaturization technologies, indicator dyes, marker proteins, cell systems, and related technologies to facilitate the development of HTS technologies related to CF drug development;
- furnishing potential therapeutic agents to evaluate as potential lead compounds for CF drug development;
- creating HTS facilities that serve as resources for evaluating prospective chemical agents resulting from combinatorial chemistry or other entities for evaluation and;
- developing chemical derivatives of existing lead compounds for consideration as candidate drugs.

The application of HTS and CC to develop new anti-*Pseudomonas aeruginosa* drugs will be considered.

Review and Award: The maximum amount awarded will be \$1.5 million over two years. Each application must contain "milestone achievement objectives" and the appropriate timetable for completion of each. Continued funding for the project will be, in part, based upon milestone attainment.

Submission: An original, plus 20 copies, must be sent to the CFF, Attn: Office of Grants Management,

6931 Arlington Road Bethesda, MD 20814 (301) 951-4422.





ENERGY SERVICE COMPANY 734 15th Street, N.W., Washington, DC 20005 202-737-8018 (Fax) 202-638-1069 Email: energy@sfp-4-hp.demon.co.uk www.sfp-4-hp.demon.co.uk

Circle No. 1 on Readers' Service Card